Company Overview
Company Type: Private Company
Website: www.neopharmlabs.com
Number of Employees: 50
Year Founded: 1990
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Neopharm Labs Inc. provides analytical testing laboratory services. The company offers portfolio validation and testing services to the life science industry, including chemistry, microbiology, sterility, quality control, research and development support, ICH stability studies, and method validation and transfers, as well as quality assurance and regulatory affairs services. It offers quality assurance and consulting services that include analytical (chemistry, chromatography, and microbiology), consulting, stability, development, and validation services; a range of stability testing and storage services; method development and validation services; microbiology and sterility testing services; and chromatography and chemistry services that include a range of methods to test raw materials, finished products, and packaging components. It serves pharmaceutical, medical devices, natural health, medical marijuana, and veterinary, as well as cosmetic clients in Canada, the United States, and internationally. The company was founded in 1990 and is based in Blainville, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 15.0
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 50
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Fortin, Nicolas
President and General Manager
Demberg, Natasha
Vice President of Operations


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
865 Michele-Bohec Boulevard | Blainville, QC | J7C 5J6 | Canada
Phone: 450 435 8864   Fax: 450 435 7595


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
MS PHARMA INC.
MS PHARMA INC. provides contract laboratory services for pharmaceutical chemistry and mass spectrometry. The company was founded in 2008 and is based in Laval, Canada. As of March 27, 2023, MS PHARMA INC. operates as a subsidiary of Neopharm Labs Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-
Averica Discovery Services Inc.
Averica Discovery Services Inc. operates as an analytical development contract research organization that specializes in small molecule analysis and purification. It offers chiral separation, impurity isolation, and analytical development services. The company was incorporated in 2007 and is headquartered in Marlborough, Massachusetts. As of November 3, 2016, Averica Discovery Services Inc. operates as a subsidiary of Neopharm Labs Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-
4131185 Canada Inc.
4131185 Canada Inc. is based in Quebec, Canada. 4131185 Canada Inc. operates as a subsidiary of Warnex Inc.

United States and Canada
-
-
-
-
Warnex Analytical Services Inc.
Warnex Analytical Services, Inc. provides consulting and analytical services in chemistry, microbiology, and chromatography to the pharmaceutical, biotechnology, and cosmetics industries. It analyzes various types of samples, such as pharmaceutical, veterinary, cosmetics, finished products, raw materials, container/packaging components, and in-process products. The company is based in Laval, Canada. As of April 2, 2012, Warnex Analytical Services Inc. operates as a subsidiary of NeoPharm Labs, Inc.

United States and Canada
Health Care Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-27-2023
Mar-27-2023
Merger/Acquisition
Buyer
MS PHARMA INC.
Neopharm Labs Inc.

-
Nov-03-2016
Nov-03-2016
Merger/Acquisition
Buyer
Averica Discovery Services Inc.
Neopharm Labs Inc.

-
Dec-3-2013
Dec-31-2013
Merger/Acquisition
Buyer
4131185 Canada Inc.
Neopharm Labs Inc.
Warnex Inc.
0.05
Jun-28-2012
Apr-30-2012
Merger/Acquisition
Target
Neopharm Labs Inc.


-
Dec-20-2011
Apr-2-2012
Merger/Acquisition
Buyer
Warnex Analytical Services Inc.
Neopharm Labs Inc.
Warnex Inc.
0.30
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Mar-27-2023
M&A Transaction Closings
Neopharm Labs Inc. acquired MS Pharma Inc.
Nov-03-2016
M&A Transaction Closings
NeoPharm Labs, Inc. acquired Averica Discovery Services Inc.
Dec-31-2013
M&A Transaction Closings
NeoPharm Labs, Inc. completed the acquisition of 4131185 Canada Inc. from Warnex Inc. (TSXV:WNX.H).
Dec-03-2013
M&A Transaction Announcements
NeoPharm Labs, Inc. entered into an agreement to acquire 4131185 Canada Inc. from Warnex Inc. (TSXV:WNX.H) for CAD 0.05 million.
Jun-28-2012
M&A Transaction Closings
A private investor acquired NeoPharm Laboratories.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Nov 04, 2016 07:25 AM
Neopharm Labs Inc.
NeoPharm Labs Acquires Averica Discovery Services
Reports
2


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Fortin, Nicolas
President and General Manager
450 435 8864
450 435 7595
-
Demberg, Natasha
Vice President of Operations
450 435 8864
450 435 7595
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
